Neurohormonal therapies at baseline and follow-up and survival in patients with wild-type transthyretin cardiac amyloidosis

18 May 2025 (11:00 - 11:45)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Alberto Aimo

Sant'Anna School of Advanced Studies, Pisa (Italy)

6 More presentations in this session

Presentation thumbnail

Cause of death in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): findings from the ATTRibute-CM study

Doctor L. Obici (Pavia, IT)

Abstract Slides Video

Presentation thumbnail

Effect of acoramidis on functional capacity and quality of life in patients with variant ATTR-CM: results from ATTRibute-CM

Professor M. Fontana (London, GB)

Abstract Slides Video

Presentation thumbnail

Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM

Professor M. Fontana (London, GB)

Abstract Slides Video

Presentation thumbnail

Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial

Assistant Professor K. Alexander (Palo Alto, US)

Abstract Slides Video

Presentation thumbnail

Bioactive adrenomedullin as a predictor of clinical outcomes in cardiac transthyretin amyloidosis

Mr M. Mueller (Berlin, DE)

Abstract Slides Video

Access the full session

Session thumbnail

Beating the odds: advances in cardiac amyloidosis treatment

The Event

Event poster

Heart Failure 2025

18 May 2025 11:00 CET

You may be interested in

Congress Session

Transthyretin amyloidosis: long-term outcomes and emerging therapies

Congress Session

Advances in cardiomyopathies

Congress Session

Therapeutic advances in amyloid cardiomyopathy

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources